GlaxoSmithKline’s new flu vaccine Fluarix was approved Wednesday for sale in the USA this fall under an accelerated FDA approval process. Another flu vaccine manufacturer, Chiron, moved closer to getting their license back; it was suspended when their flu vaccine was found to be contaminated with bacteria.
Chiron’s license was suspended by British regulators in October, and the FDA barred U.S. distribution of the vaccine, cutting the nation’s expected supply of flu vaccine in half.
GlaxoSmithKline expects to distribute 8 million doses of Fluarix and will begin shipping immediately. Chiron, if its vaccine is re-approved, could supply 18 million to 26 million doses of Fluvirin.
Dr. Mercola’s Comment:
It has been six years since the American Academy of Pediatrics and the U.S. Public Health Service joined forces in requesting the removal of all mercury-containing preservative thimerosal from vaccines.
A quick surf on the net easily reveals that this new vaccine indeed contains mercury.